Richard Marsden
Chief Executive Officer chez SYNAIRGEN PLC
Fortune : 64 088 $ au 31/03/2024
Profil
Richard James Marsden is currently the Chief Executive Officer & Executive Director at Synairgen Plc since 2009.
He is also a Director at Synairgen Research Ltd.
since 2004.
Previously, he worked as the Respiratory Director at MedImmune Ltd.
He was the Managing Director at Southampton Asset Management Ltd.
from 2005 to 2014.
Before that, he served as the Manager-Cystic Fibrosis Business Development at Respironics Ltd.
from 1998 to 2003.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SYNAIRGEN PLC
0,49% | 31/12/2022 | 995 771 ( 0,49% ) | 64 088 $ | 31/03/2024 |
Postes actifs de Richard Marsden
| Sociétés | Poste | Début |
|---|---|---|
| SYNAIRGEN PLC | Chief Executive Officer | 01/06/2004 |
Synairgen Research Ltd.
 Synairgen Research Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Synairgen Plc, Synairgen Research Ltd. is a British company that engages in respiratory biology and develops novel therapies. The private company is based in Southampton, UK. Synairgen Research was founded in 2003. | Director/Board Member | 07/06/2004 |
Anciens postes connus de Richard Marsden
| Sociétés | Poste | Fin |
|---|---|---|
Southampton Asset Management Ltd.
 Southampton Asset Management Ltd. Investment ManagersFinance Southampton Asset Management Ltd (SAM) is a venture capital firm, a subsidiary of University of Southampton Holdings Ltd. The firm is headquartered in Southampton, United Kingdom. | Director/Board Member | 17/03/2014 |
Respironics Ltd.
 Respironics Ltd. Financial ConglomeratesFinance Respironics Ltd. develops and manufactures medical and healthcare products. Its products include Porta-Neb, Freeway Freedom, Sidestream, and Ventstream. The company was founded in 1977 and is headquartered in Bognor Regis, the United Kingdom. | Corporate Officer/Principal | 01/01/2003 |
MedImmune Ltd.
 MedImmune Ltd. BiotechnologyHealth Technology MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SYNAIRGEN PLC | Health Technology |
| Entreprise privées | 4 |
|---|---|
MedImmune Ltd.
MedImmune Ltd. BiotechnologyHealth Technology MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Respironics Ltd.
Respironics Ltd. Financial ConglomeratesFinance Respironics Ltd. develops and manufactures medical and healthcare products. Its products include Porta-Neb, Freeway Freedom, Sidestream, and Ventstream. The company was founded in 1977 and is headquartered in Bognor Regis, the United Kingdom. | Finance |
Southampton Asset Management Ltd.
Southampton Asset Management Ltd. Investment ManagersFinance Southampton Asset Management Ltd (SAM) is a venture capital firm, a subsidiary of University of Southampton Holdings Ltd. The firm is headquartered in Southampton, United Kingdom. | Finance |
Synairgen Research Ltd.
Synairgen Research Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Synairgen Plc, Synairgen Research Ltd. is a British company that engages in respiratory biology and develops novel therapies. The private company is based in Southampton, UK. Synairgen Research was founded in 2003. | Commercial Services |
